title: Sacubitril/valsartan, ivabradine hydrochloride, alirocumab, and evolocumab.
authors.affiliation: Philadelphia College of Pharmacy, University of the Sciences, Philadelphia, PA.
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Hussar
authors.affiliation: Philadelphia College of Pharmacy, University of the Sciences, Philadelphia, PA.
authors.forename: Marina
authors.initials: M
authors.lastname: Abdelsayed
mesh_terms: D000613:Aminobutyrates / Q000009:adverse effects / Q000627:therapeutic use*; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000924:Anticholesteremic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001552:Benzazepines / Q000009:adverse effects / Q000627:therapeutic use*; D001713:Biphenyl Compounds; D004338:Drug Combinations; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000077550:Ivabradine; D013777:Tetrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D000068756:Valsartan
chemical_list: D000613:Aminobutyrates; D000889:Anti-Arrhythmia Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000924:Anticholesteremic Agents; D001552:Benzazepines; D001713:Biphenyl Compounds; D004338:Drug Combinations; D007004:Hypoglycemic Agents; D013777:Tetrazoles; D000077550:Ivabradine; D000068756:Valsartan; C577155:evolocumab; C571059:alirocumab; C549068:sacubitril and valsartan sodium hydrate drug combination